Insights

Why is the Race Oncology (ASX:RAC) share price plunging 12% today?

It hasn’t been a good day for the precision oncology company.
The post Why is the Race Oncology (ASX:RAC) share price plunging 12% today? appeared first on The Motley Fool Australia. –

Investors are selling off shares in precision oncology company Race Oncology Ltd (ASX: RAC) after a flurry of market sensitive announcements yesterday.

At the time of writing, shares in the RNA focused company are down around 12.47% at $3.30, as investors digest the updates announced after the bell on Tuesday.

What did Race Oncology announce?

Race Oncology came out with several updates, including presentations from its AGM and advising of a share purchase plan (SPP).

The Company is intending to raise up to $29.7 million under the SPP. Eligible shareholders will have the opportunity to acquire fully paid ordinary shares in Race Oncology under the terms.

Shares will be issued at a price of $3 under the SPP. This is at a discount of 20.4% to Race Oncology’s last closing price.

Race Oncology has taken the liberty of providing three scenarios in which the funds will be raised and allocated.

In its best-case scenario, it hopes to raise the $29.7 million in order to finance various cancer and AML/MDS studies, whilst improving the formulation of its lead drug candidate called Zantrene.

Whereas in its base scenario, it hopes to raise $12 million and would narrow its study focus whilst refining the Zantrene formula.

Aside from this, Race Oncology also released the presentation from its AGM yesterday. In it, the company provided a strategic update to its “Three Pillar” strategy.

This involves extending Zantrene’s use to the “new area of cardio-protection, enhancing Zantrene’s utility for solid tumours through new formulations, and commencing a program to develop new RNA–targeting molecules”.

Speaking on the AGM, Race Oncology’s CEO and Managing Director Phil Lynch said:

2020-2021 has seen significant progress for Race. We have built a select and highly capable team, which has planned and completed important pre-clinical programs that positively capitalise on the FTO opportunity, most
recently reported for melanoma. We have also generated unexpectedly positive new preclinical data and insight indicating Zantrene provides cardio-protection, when used adjunctively with a traditional anthracycline chemotherapeutic. This is both a significant preclinical observation as well as a potentially large commercial opportunity for Race given there are few products that compete in this field.

The announcements follow an update out of Race’s corner on Monday. Investors bid up the Race Oncology share price following study readouts for Zantrene in a heart safety research program.

Race Oncology share price snapshot

Investors have responded poorly to the announcements today, driving the company’s share price down with force.

For instance, total trading volume today is over 445% of the 4-week average for Race Oncology shares at 1,148,215.

The Race Oncology share price is also down almost 6% in the past week of trading, however, has climbed over 89% this year to date.

As such it is well ahead of the benchmark S&P/ASX 200 index (ASX: XJO)’s gain of around 12% since January 1.

The post Why is the Race Oncology (ASX:RAC) share price plunging 12% today? appeared first on The Motley Fool Australia.

Should you invest $1,000 in Race Oncology right now?

Before you consider Race Oncology, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Race Oncology wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Why Bapcor, Mayne Pharma, Race Oncology, and TechnologyOne shares are sinking

Racing higher: Race Oncology (ASX:RAC) share price jumps 13% on study breakthrough

Why the Race Oncology (ASX:RAC) share price is up on Monday

Race Oncology (ASX:RAC) share price struggles despite new Leukemia study

The author has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!